Cargando…
Efficacy and Safety of Intravenous Ferric Carboxymaltose Treatment of Iron Deficiency Anaemia in Patients with Corpus Atrophic Gastritis: A Retrospective Study
Corpus Atrophic Gastritis (CAG) is characterised by iron malabsorption leading to iron deficiency anaemia (IDA), which rarely responds to oral therapy. Ferric carboxymaltose (FCM), shown to be a safe and effective intravenous iron therapy in other diseases, has not been investigated yet in CAG. Thus...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574262/ https://www.ncbi.nlm.nih.gov/pubmed/37836482 http://dx.doi.org/10.3390/nu15194199 |
_version_ | 1785120652671320064 |
---|---|
author | Dottori, Ludovica Corleone Tsar'kov, Daniil Dilaghi, Emanuele Pivetta, Giulia Scalamonti, Silvia Ligato, Irene Esposito, Gianluca Annibale, Bruno Lahner, Edith |
author_facet | Dottori, Ludovica Corleone Tsar'kov, Daniil Dilaghi, Emanuele Pivetta, Giulia Scalamonti, Silvia Ligato, Irene Esposito, Gianluca Annibale, Bruno Lahner, Edith |
author_sort | Dottori, Ludovica |
collection | PubMed |
description | Corpus Atrophic Gastritis (CAG) is characterised by iron malabsorption leading to iron deficiency anaemia (IDA), which rarely responds to oral therapy. Ferric carboxymaltose (FCM), shown to be a safe and effective intravenous iron therapy in other diseases, has not been investigated yet in CAG. Thus, we aimed to assess the safety and efficacy of FCM in CAG-related IDA. A retrospective study on 91 patients identified CAG as the only cause of IDA treated with FCM. Twenty-three were excluded for incomplete follow-up. Sixty-eight were evaluated for safety and efficacy, while three were evaluated for safety only due to infusion interruption for side effects. Haemoglobin and iron storage were evaluated pre-infusion (T0), at 4 weeks (T4) and 12 weeks (T12) after infusion. An eventual IDA relapse was analysed. Two cases reported mild side effects. Haemoglobin significantly increased at T4, and T12, reaching +3.1 g/dL. Ferritin increased at T4, decreasing at T12, while transferrin saturation increased progressively until reaching a plateau. IDA relapsed in 55.4% of patients at a mean of 24.6 months. The only factor associated with relapse was female gender [OR (95% CI): 6.6 (1.5–28.6)]. FCM proved to be safe and effective in treating CAG-related IDA, ensuring quick and long-lasting recovery. |
format | Online Article Text |
id | pubmed-10574262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105742622023-10-14 Efficacy and Safety of Intravenous Ferric Carboxymaltose Treatment of Iron Deficiency Anaemia in Patients with Corpus Atrophic Gastritis: A Retrospective Study Dottori, Ludovica Corleone Tsar'kov, Daniil Dilaghi, Emanuele Pivetta, Giulia Scalamonti, Silvia Ligato, Irene Esposito, Gianluca Annibale, Bruno Lahner, Edith Nutrients Article Corpus Atrophic Gastritis (CAG) is characterised by iron malabsorption leading to iron deficiency anaemia (IDA), which rarely responds to oral therapy. Ferric carboxymaltose (FCM), shown to be a safe and effective intravenous iron therapy in other diseases, has not been investigated yet in CAG. Thus, we aimed to assess the safety and efficacy of FCM in CAG-related IDA. A retrospective study on 91 patients identified CAG as the only cause of IDA treated with FCM. Twenty-three were excluded for incomplete follow-up. Sixty-eight were evaluated for safety and efficacy, while three were evaluated for safety only due to infusion interruption for side effects. Haemoglobin and iron storage were evaluated pre-infusion (T0), at 4 weeks (T4) and 12 weeks (T12) after infusion. An eventual IDA relapse was analysed. Two cases reported mild side effects. Haemoglobin significantly increased at T4, and T12, reaching +3.1 g/dL. Ferritin increased at T4, decreasing at T12, while transferrin saturation increased progressively until reaching a plateau. IDA relapsed in 55.4% of patients at a mean of 24.6 months. The only factor associated with relapse was female gender [OR (95% CI): 6.6 (1.5–28.6)]. FCM proved to be safe and effective in treating CAG-related IDA, ensuring quick and long-lasting recovery. MDPI 2023-09-28 /pmc/articles/PMC10574262/ /pubmed/37836482 http://dx.doi.org/10.3390/nu15194199 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Dottori, Ludovica Corleone Tsar'kov, Daniil Dilaghi, Emanuele Pivetta, Giulia Scalamonti, Silvia Ligato, Irene Esposito, Gianluca Annibale, Bruno Lahner, Edith Efficacy and Safety of Intravenous Ferric Carboxymaltose Treatment of Iron Deficiency Anaemia in Patients with Corpus Atrophic Gastritis: A Retrospective Study |
title | Efficacy and Safety of Intravenous Ferric Carboxymaltose Treatment of Iron Deficiency Anaemia in Patients with Corpus Atrophic Gastritis: A Retrospective Study |
title_full | Efficacy and Safety of Intravenous Ferric Carboxymaltose Treatment of Iron Deficiency Anaemia in Patients with Corpus Atrophic Gastritis: A Retrospective Study |
title_fullStr | Efficacy and Safety of Intravenous Ferric Carboxymaltose Treatment of Iron Deficiency Anaemia in Patients with Corpus Atrophic Gastritis: A Retrospective Study |
title_full_unstemmed | Efficacy and Safety of Intravenous Ferric Carboxymaltose Treatment of Iron Deficiency Anaemia in Patients with Corpus Atrophic Gastritis: A Retrospective Study |
title_short | Efficacy and Safety of Intravenous Ferric Carboxymaltose Treatment of Iron Deficiency Anaemia in Patients with Corpus Atrophic Gastritis: A Retrospective Study |
title_sort | efficacy and safety of intravenous ferric carboxymaltose treatment of iron deficiency anaemia in patients with corpus atrophic gastritis: a retrospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574262/ https://www.ncbi.nlm.nih.gov/pubmed/37836482 http://dx.doi.org/10.3390/nu15194199 |
work_keys_str_mv | AT dottoriludovica efficacyandsafetyofintravenousferriccarboxymaltosetreatmentofirondeficiencyanaemiainpatientswithcorpusatrophicgastritisaretrospectivestudy AT corleonetsarkovdaniil efficacyandsafetyofintravenousferriccarboxymaltosetreatmentofirondeficiencyanaemiainpatientswithcorpusatrophicgastritisaretrospectivestudy AT dilaghiemanuele efficacyandsafetyofintravenousferriccarboxymaltosetreatmentofirondeficiencyanaemiainpatientswithcorpusatrophicgastritisaretrospectivestudy AT pivettagiulia efficacyandsafetyofintravenousferriccarboxymaltosetreatmentofirondeficiencyanaemiainpatientswithcorpusatrophicgastritisaretrospectivestudy AT scalamontisilvia efficacyandsafetyofintravenousferriccarboxymaltosetreatmentofirondeficiencyanaemiainpatientswithcorpusatrophicgastritisaretrospectivestudy AT ligatoirene efficacyandsafetyofintravenousferriccarboxymaltosetreatmentofirondeficiencyanaemiainpatientswithcorpusatrophicgastritisaretrospectivestudy AT espositogianluca efficacyandsafetyofintravenousferriccarboxymaltosetreatmentofirondeficiencyanaemiainpatientswithcorpusatrophicgastritisaretrospectivestudy AT annibalebruno efficacyandsafetyofintravenousferriccarboxymaltosetreatmentofirondeficiencyanaemiainpatientswithcorpusatrophicgastritisaretrospectivestudy AT lahneredith efficacyandsafetyofintravenousferriccarboxymaltosetreatmentofirondeficiencyanaemiainpatientswithcorpusatrophicgastritisaretrospectivestudy |